STAb-T19
Relapsed/Refractory CD19+ B-cell malignancies (e.g., B-ALL, B-cell lymphomas)
Pre-clinicalActive
Key Facts
Indication
Relapsed/Refractory CD19+ B-cell malignancies (e.g., B-ALL, B-cell lymphomas)
Phase
Pre-clinical
Status
Active
Company
About STAb Therapeutics
STAb Therapeutics, a 2018 spin-off from the Research Institute Hospital 12 de Octubre (imas12), is pioneering a novel T cell redirecting immunotherapy. Its STAb platform engineers T cells to secrete T cell engagers (TCEs) in vivo, aiming to enhance anti-tumor responses through sustained drug levels and recruitment of bystander T cells. The company is advancing its lead candidate, STAb-T19 for B-cell malignancies, towards clinical trials, supported by non-dilutive grants from Spanish public entities. It operates as a private, preclinical-stage biotech based in Madrid.
View full company profile